Recent advances in estrogen-signaling and new sites for pharmacological interventions
作者单位：Department of Biosciences and Nutrition NOVUM Karolinska Institutet Stockholm
会议名称：《第十五届国际药理学大会》
会议日期：2006年
学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 100602[医学-中西医结合临床] 10[医学]
摘 要：正 Both in vitro and in vivo. ERβ acts as an antiproliferative principle in several tissues, e g the prostate where ERβ is antiproliferative. proapoptotic and prodifferentiative. An ERβ agonist developed by Eli Lilly shows all of the anticipated biological effects on the prostate, namely reduced cellular proliferation and increased apoptosis, leading to a diminished size of both mouse and rat prostate. This opens up hitherto unthought-of pharmaceutical possibilities in treating prostate disorders in humans, including both benign prostatic hyperplasia and prostate carcinoma. It now appears quite clear that ERβ also exerts an antiproliferative effect on human breast cancer cells both in vitro and in vivo;there seems to be sufficient indications for a pharmaceutical potential of ERβ agonists in treatment of breast cancer. A similar case can be made for use of ERβ agonists in treatment of colon cancer. Furthermore. ERβ is of major importance in estrogenic regulation of the immune system. Wyeth-Ayerst has reported extremely encouraging results of ERβ agonists in treatment of rodent models of inflammatory bowel disease （IBD）. rheumatoid arthritis and endometriosis.